Biotech ValuationsValuations across much of the biotech space have continued to pull back and reset, affecting MetaVia stock as well.
Capital RequirementsThe company will likely need to raise capital soon, which is a concern for investors.
Stock Price PressureShares of MTVA are under pressure, down ~20%, stemming from a combination of misunderstanding of the data itself and activity in the obesity/metabolic space from Merck.